Table 1.
Patient characteristics
| Characteristics | LDRB group, n (%) | HDRB Group, n (%) |
Entire cohort, n (%) | P value |
|---|---|---|---|---|
| No. of patients | 15 (48.4) | 16 (51.6) | 31 | |
| Median age (IQR) | 63 (61-68) | 66 (61-72) | 64 (61-70) | .59∗ |
| ECOG performance status | 0 | 0 | 0 | 1∗ |
| Pretreatment PSA median (IQR) | 5.37 (4.9-7.8) | 6.35 (4.9-8.7) | 5.6 (4.8-8.3) | .4∗ |
| Gleason score | .6∗ | |||
| 6 | 5 (33.3) | 7 (43.8) | 12 (38.7) | |
| 7 | 10 (66.7) | 9 (56.3) | 19 (61.3) | |
| Clinical stage | .7∗ | |||
| T1c | 12 (80) | 12 (75) | 24 (77.4) | |
| T2a | 3 (20) | 4 (25) | 7 (22.6) | |
| Pretreatment IPSS, median (IQR) | 8 (4-10) | 5 (1-8) | 7 (2-9) | .12∗ |
| Pretreatment EPIC urinary incontinence, mean (range) | 93.6 | 97.3 | 95.3 | .35† |
| Pretreatment EPIC urinary Irritative, mean (range) |
89.3 | 90.6 | 89.9 | .7† |
| Pretreatment EPIC sexual, mean (range) | 70.4 | 63.6 | 67.1 | .5† |
| Pretreatment EPIC bowel, median (IQR) | 97.2 | 97.1 | 97.2 | .9† |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; EPIC = Expanded Prostate Cancer Index Composite; HDRB = high-dose-rate brachytherapy; IQR = interquartile range; LDRB = low-dose-rate brachytherapy; PSA = prostate specific antigen.
∗
P value calculated using Kruskal-Wallis test.
†
P value calculated using Student t test.